MSH2 and ovarian carcinoma: Similarly, this prevalence was confirmed in ovarian cancer with MSI-H, with genomic alteration rates of MSH6, MSH2, MLH1, and PMS2 of 52.6%, 36.8%, 31.6%, and 10.5%, respectively.